Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study by de Pont, Anne-Cornélie JM et al.
Open Access
Available online http://ccforum.com/content/11/5/R102
Page 1 of 5
(page number not for citation purposes)
Vol 11 No 5 Research
Pharmacokinetics and pharmacodynamics of danaparoid during 
continuous venovenous hemofiltration: a pilot study
Anne-Cornélie JM de Pont1, Jorrit-Jan H Hofstra1,2, Derk R Pik3,  J o o s tC MM e i j e r s 4 and 
Marcus J Schultz1,2
1Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ 
Amsterdam, The Netherlands
3Faculty of Science, University of Leiden, Niels Bohrweg 1, 2333 CA Leiden, The Netherlands
4Laboratory of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The 
Netherlands
Corresponding author: Anne-Cornélie JM de Pont, a.c.depont@amc.uva.nl
Received: 22 Jun 2007 Revisions requested: 25 Jul 2007 Revisions received: 27 Aug 2007 Accepted: 13 Sep 2007 Published: 13 Sep 2007
Critical Care 2007, 11:R102 (doi:10.1186/cc6119)
This article is online at: http://ccforum.com/content/11/5/R102
© 2007 de Pont et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background In patients with suspected heparin-induced
thrombocytopenia (HIT) who need renal replacement therapy, a
nonheparin anticoagulant has to be chosen to prevent
thrombosis in the extracorporeal circuit. Danaparoid, a low-
molecular-weight heparinoid consisting of heparan sulphate,
dermatan sulphate, and chondroitin sulphate, is recommended
for systemic anticoagulation in patients with HIT. However, there
are few data on the use of danaparoid in patients with acute
renal failure, especially in patients dependent on renal
replacement therapy such as continuous venovenous
hemofiltration (CVVH). In the present study, we analyzed the
pharmacokinetics and pharmacodynamics of danaparoid during
CVVH in patients with suspected HIT.
Methods Based on a mathematical model, a dosing scheme for
danaparoid was designed, aiming at anti-Xa levels of 0.5 to 0.7
U/mL, with a maximum of 1.0 U/mL. This dosing scheme was
prospectively tested in the first CVVH run of a cohort of five
patients with suspected HIT. CVVH with a blood flow rate of
150 mL/minute and a substitution rate of 2,000 mL/hour was
performed with a cellulose triacetate membrane. Danaparoid
was administered as a continuous infusion of 100 anti-Xa-U/
hour after a loading dose of 3,500 anti-Xa-U. Serial
measurements of anti-Xa activity and prothrombin fragment
F1+2 were performed at baseline, at t = 5, 15, and 30 minutes,
and at t = 1, 2, 4, 8, 16, and 24 hours after the danaparoid
loading dose.
Results The median anti-Xa activity reached a maximum of 1.02
(0.66 to 1.31) anti-Xa-U/mL after 15 minutes and gradually
declined to 0.40 (0.15 to 0.58) anti-Xa-U/mL over the span of
24 hours. Target anti-Xa levels were reached from 2 to 12 hours
after the loading dose. Median prothrombin fragment F1+2
gradually decreased from 432 (200 to 768) to 262 (248 to 317)
pmol/L after 24 hours. No bleeding or thromboembolic events
occurred throughout the described treatment period.
Conclusion Danaparoid administered by a continuous infusion
of 100 anti-Xa-U/hour after a loading dose of 3,500 anti-Xa-U
elicited target anti-Xa levels from 2 to 12 hours after the loading
dose, without bleeding or thromboembolic events during the
described CVVH treatment in patients with suspected HIT.
Introduction
During continuous venovenous hemofiltration (CVVH), antico-
agulation with unfractionated heparin is commonly used to
prevent thrombosis in the extracorporeal circuit. However, in
patients with suspected heparin-induced thrombocytopenia
(HIT), another anticoagulant has to be chosen. Because
patients with HIT have a 25% to 50% risk of symptomatic
thrombosis, systemic anticoagulation is indicated [1]. In the
American College of Chest Physicians guidelines for recogni-
tion, prevention, and treatment of HIT, direct thrombin inhibi-
tors and danaparoid are recommended for systemic
anticoagulation in patients with HIT [1]. Danaparoid is a low-
CVVH = continuous venovenous hemofiltration; ELISA = enzyme-linked immunosorbent assay; F1+2 = prothrombin fragment F1+2; HIT = heparin-
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molecular-weight heparinoid consisting of a mixture of
heparan sulphate (84%), dermatan sulphate (12%), and small
amounts of chondroitin sulphate (4%). Its pharmacological
effect is exerted primarily by the inhibition of factors Xa and IIa
at a ratio greater than that of unfractionated heparin [2].
Although extensive experience with danaparoid has been
gained in the clinical setting, there are few data on its use in
patients with acute renal failure, especially in patients depend-
ent on CVVH. Under normal conditions, the elimination of dan-
aparoid is predominantly renal, with an elimination half-life of
25 hours. During CVVH, danaparoid can be removed only by
means of a polyarylethersulphone membrane, with a sieving
coefficient of 0.78 ± 0.03 [3]. Therefore, treatment with a con-
tinuous infusion of danaparoid carries the risk of accumulation
in patients with acute renal failure dependent on CVVH.
Because an antidote is lacking, this accumulation may entail
an increased risk of bleeding. The recommended dose for anti-
coagulation with danaparoid in HIT patients requiring CVVH is
an intravenous (IV) loading dose of 2,250 anti-Xa-U followed
by a continuous infusion of 600 anti-Xa-U/hour for the first 4
hours, 400 anti-Xa-U/hour for the next 4 hours, and then 200
to 400 anti-Xa-U/hour adjusted by anti-Xa level [4]. A thera-
peutic anti-Xa level is 0.5 to 0.7 anti-Xa-U/mL, with a maximum
of 1.0 anti-Xa-U/mL. However, using the recommended dos-
ing scheme, our patients frequently experienced bleeding,
especially when peak anti-Xa levels exceeded 1.0 anti-Xa-U/
mL. In a retrospective analysis, we found a linear relationship
between the peak anti-Xa level and the need of red blood cell
transfusions in patients with a peak anti-Xa level of greater
than 0.7 anti-Xa-U/mL (r2 = 0.55; p = 0.02) (ACJM de Pont,
JJH Hofstra, DR Pik, JCM Meijers, MJ Schultz, unpublished
data). Therefore, we decided to design a safer dosing scheme
for danaparoid, based on a mathematical model aiming at a
peak anti-Xa level of less than 1.0 and a maintenance level of
between 0.5 and 0.7 anti-Xa-U/mL. Lindhoff-Last and col-
leagues [5] have suggested that a loading dose of 750 anti-
Xa-U IV followed by a maintenance dose of 50 to 150 anti-Xa-
U/hour might be sufficient to maintain a safe and effective level
of anticoagulation. However, serial pharmacokinetic measure-
ments to confirm this hypothesis have never been published.
The aim of the present study was to determine the pharmacok-
inetic and pharmacodynamic properties of danaparoid in
patients with suspected HIT treated with CVVH, using a new
dosing scheme based on a mathematical model.
Materials and methods
Patients and study design
The observations in this study were made in the context of
standardized protocol for routine patient care. Our institutional
review board waived a formal approval procedure for the
study. Eligible patients were suspected of HIT and had acute
renal failure necessitating CVVH. Suspicion of HIT was based
on the 4T score: (a) a more than 50% decrease in platelet
count after exposure to heparin, (b) timing of the decrease in
platelet count compatible with HIT, (c) a new thrombosis, skin
necrosis, or an acute systemic reaction after heparin adminis-
tration, and (d) absence of other causes of thrombocytopenia
[6]. In addition, antibodies against heparin/platelet factor 4
(PF4) complex were detected by means of enzyme-linked
immunosorbent assay (ELISA). The exclusion criterion was
overt bleeding or a manifest clotting disorder defined as a pro-
thrombin time or an activated partial thromboplastin time of
more than 1.5 times the upper limit of normal. Enrolled patients
were studied for the duration of the first CVVH run in which
danaparoid was used as an anticoagulant.
Hemofiltration procedure
Vascular access was obtained by insertion of a double-lumen
catheter (Duo-Flow 400XL, 14F × 6 inches (15 cm); Med-
comp, Harleysville, PA, USA) into a large vein (femoral, subcla-
vian, or internal jugular vein). CVVH was performed using a
Diapact hemofiltration machine (B. Braun Melsungen AG,
34212 Melsungen, Germany) and a cellulose triacetate hemo-
filter (CT-190G; Baxter Healthcare Corp., Deerfield, IL, USA).
The ultrafiltration rate was set at 2,000 mL/hour, and a bicar-
bonate-buffered substitution fluid was administered in predilu-
tion mode with a flow of 2,000 mL/hour. The blood flow was
set at 150 mL/minute, and a negative fluid balance was
allowed. Circuit survival time was defined as the time elapsed
from starting CVVH until clotting of the extracorporeal circuit.
Mathematical model
Given a loading dose B (in anti-Xa-U) added to a total plasma
volume of 3,500 mL and assuming an elimination half-life of 25
hours, the concentration at time point t will be 2-t/25 times B/
3,500 anti-Xa-U/mL. By adding a continuous dose D (in anti-
Xa-U) per hour, the plasma concentration C(t) at time point t
(in anti-Xa-U/mL) can be approximated by the formula
where α = 21/25. Ideally, the plasma concentration should be
between 0.5 and 0.7 anti-Xa-U/mL. Thus, the value D is
obtained by taking time to infinity, which yields D = 0.7 ×
3.500 × (α - 1) anti-Xa-U, and consequently the loading dose
B can be found as the maximal value for which the concentra-
tion does not exceed the value of 1.0 anti-Xa-U/mL.
Anticoagulation
The extracorporeal circuit was not primed with any anticoagu-
lant. Based on the mathematical model, the danaparoid load-
ing dose B was calculated to be 3,500 anti-Xa-U and the
continuous dose D to be 100 anti-Xa-U/hour. The CVVH pro-
cedure was started immediately after administration of the
danaparoid loading dose of 3,500 anti-Xa-U followed by a
continuous danaparoid infusion of 100 anti-Xa-U/hour.
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Blood collection, laboratory assays, and statistical 
analysis
Blood was collected in citrated vacutainer tubes at baseline,
at t = 5, 15, and 30 minutes, and at t = 1, 2, 4, 8, 16, and 24
hours after the danaparoid loading dose and was processed
immediately. Plasma was prepared by centrifugation at 2,500
g twice for 20 minutes at 16°C followed by storage at -80°C
until assays were performed. Antibodies against heparin/PF4
complex were detected by ELISA (GTI PF4 HAT 45; Diagast,
Loos, France). Anti-Xa activity was determined with Berichrom
Heparin on a Behring Coagulation System (both from Dade
Behring Marburg GmbH, Marburg, Germany). To assess the
process of thrombin generation during CVVH, prothrombin
fragments F1+2 (F1+2) were measured by ELISA (Enzygnost
F1+2 [monoclonal]; Dade Behring Marburg GmbH). Normal
values for F1+2 range from 300 to 1,600 pmol/L. Data are
reported as median and range. Changes in coagulation param-
eters over time were compared by means of a paired Student's
t test. Circuit survival times were compared with those previ-
ously published in the literature by means of Student's t test.
A p value of less than 0.05 was considered significant.
Results
Patient characteristics
Five critically ill patients with acute renal failure and suspicion
of HIT were studied. All patients had a previous exposure to
heparin in the past 30 days, and in all patients the platelet
count decreased more than 50% within 1 day after rechal-
lenge. Two patients suffered from skin necrosis, and in no
patient could a definite alternative cause for the thrombocyto-
penia be found. For all patients, 4T scores were calculated;
these are summarized in Table 1. All patients had a 4T score
compatible with an intermediate (4 to 5) or high (6 to 8) prob-
ability of HIT. With the exception of patient 2, all patients had
positive antibodies against the heparin/PF4 complex.
Pharmacokinetics and pharmacodynamics of 
danaparoid during continuous venovenous 
hemofiltration
Median anti-Xa activity reached a maximum of 1.02 (0.66 to
1.31) U/mL at t = 15 minutes (p = 0.001 compared with t =
0) and gradually declined to 0.40 (0.15 to 0.58) U/mL over the
span of 24 hours (p < 0.05 compared with t = 15 minutes).
The half-life of the anticoagulant effect as calculated from
these data was 8 hours. Mean prothrombin fragment F1+2
decreased from 432 (200 to 768) to 326 (131 to 697) pmol/
L at t = 5 minutes (p < 0.05) and did not change significantly
thereafter (Figure 1).
Complications
No clinically important bleeding events or thromboembolic
complications occurred in any of the five patients during the
described CVVH treatment.
Circuit survival times
The individual circuit survival times reached with danaparoid
as an anticoagulant during CVVH are reported in Table 1. A
median circuit survival time of 50.2 (20 to 89) hours was
achieved.
Discussion
In this small prospective cohort study, we demonstrated that
using danaparoid in a loading dose of 3,500 anti-Xa-U IV fol-
lowed by a continuous infusion of 100 anti-Xa-U/hour, the
median peak anti-Xa level reached was slightly too high,
whereas the median anti-Xa level fell below the target range of
0.5 to 0.7 U/mL after 12 hours. Thrombin generation remained
within the normal range during the first 6 hours. To our knowl-
edge, this is the first time the pharmacokinetics and pharma-
codynamics of danaparoid have been studied during CVVH. A
limitation of this study is that we used an ultrafiltration rate of
2 L/hour, which is lower than the 35 mL/kg per hour proven by
Ronco and colleagues [7] to be most effective. Additional
Table 1
Characteristics of the enrolled patients
Patient Gender Age (years) Body weight 
(kg)
Diagnosis Etiology of 
ARF
Type of ARF APACHE II 
score
4T score Circuit 
survival time 
(hours)
1 Male 76 75 Ventricular rupture Cardiac 
failure
Nonoliguric 23 4 62.3
2 Female 76 72 Post-CABG × 5 Cardiac 
failure
Oliguric 20 8 50.2
3 Female 71 62 Rectal resection Sepsis Oliguric 24 4 20.0
4 Female 65 70 Post-CABG × 3 Cardiac 
failure
Oliguric 21 8 89.0
5 Male 75 70 Post-CABG × 5 Cardiac 
failure
Oliguric 20 5 29.3
4T score, probability score for heparin-induced thrombocytopenia, based on extent, timing, and cause of thrombocytopenia and complications of 
heparin administration; APACHE II, Acute Physiology And Chronic Health Evaluation II; ARF, acute renal failure; CABG, coronary artery bypass 
grafting.Critical Care    Vol 11 No 5    de Pont et al.
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studies are needed to determine the optimal danaparoid dos-
ing scheme during CVVH with an ultrafiltration rate of 35 mL/
kg per hour or more.
Although in our cohort the median anti-Xa activity dropped
below 0.5 U/mL after 12 hours, we achieved median circuit
survival times similar to those reported by Lindhoff-Last and
colleagues [5]: 50.2 (20 to 89) hours versus 36 (24 to 70)
hours (p value not significant). However, their mean circuit sur-
vival time was achieved with a lower loading dose (or no load-
ing dose at all) followed by a continuous infusion varying from
90 to 225 anti-Xa-U/hour, reaching a mean anti-Xa activity var-
ying from 0.33 to 0.89 U/mL. In addition, Lindhoff-Last and
colleagues reported that with continuous venovenous hemodi-
alysis, an even lower dose of danaparoid was effective: with a
loading dose of 750 anti-Xa-U IV followed by a continuous
infusion varying from 64 ± 10 to 315 ± 163 anti-Xa-U/hour, an
anti-Xa activity of 0.23 ± 0.13 to 0.53 ± 0.17 U/mL was
reached. Unfortunately, the circuit survival times achieved with
this dose were not reported. However, in a study on anticoag-
ulation with low-molecular-weight heparins during CVVH, we
did not find a relationship between anti-Xa activity and circuit
survival time: with a maximum anti-Xa activity of 0.46 ± 0.14 U/
mL gradually declining over the span of 24 hours, a circuit sur-
vival time of 15.4 ± 7.4 hours was reached [8]. This finding
confirmed an earlier finding by Journois and colleagues [9],
who did not find a relationship between anti-Xa levels and cir-
cuit survival times either. A recent randomized controlled
crossover study among 40 critically ill patients also failed to
establish a correlation between anti-Xa levels and filter survival
[10].
Because bleeding complications are related to the anti-Xa
activity reached [11], it is important to use the lowest possible
dose of danaparoid that is still effective during CVVH. As can
be calculated by our proposed formula, this might be achieved
by lowering the loading dose, the level of continuous infusion,
or both. Given that a loading dose of 3,500 anti-Xa-U IV led to
a median maximum anti-Xa activity of 1.02 (0.66 to 1.31) U/
mL, lowering the loading dose is recommended. Continuous
infusion of 100 IU/hour was effective, as anti-Xa activities
remained within the target range during the first 12 hours,
leading to acceptable circuit survival times. Additional studies
are needed to determine the lowest danaparoid dose for both
loading and continuous infusion necessary to keep the circuit
open.
Conclusion
This study demonstrated that danaparoid in a loading dose of
3,500 IU IV followed by a continuous infusion of 100 IU/hour
was effective at keeping the extracorporeal circuit open, with
median anti-Xa activities within the therapeutic range from 2 to
12 hours after the loading dose and without any bleeding or
thomboembolic complications during the described treatment
period.
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Key messages
￿  When danaparoid was used as an anticoagulant during 
continuous venovenous hemofiltration, a loading dose 
of 3,500 IU IV followed by a continuous infusion of 100 
IU/hour led to target anti-Xa levels of 0.5 to 0.7 U/mL 
from 2 to 12 hours after the loading dose.
￿  To reach a peak anti-Xa level within the target range, the 
loading dose should be lowered according to the math-
ematical formula, aiming at a peak anti-Xa level of 0.5 to 
0.7 U/mL.
￿  When danaparoid was administered as a continuous 
infusion of 100 IU/hour after a loading dose of 3,500 IU, 
a median circuit survival time of 50.2 hours was 
reached, while no clinically important bleeding events or 
thromboembolic complications occurred during the par-
ticular hemofiltration run.